Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials. [PDF]
, 2018 AimsThis analysis assessed the efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, in patients with or without metabolic syndrome (MetS) using pooled data from 10 phase 3 ODYSSEY trials.Materials and methodsData ...
Bujas-Bobanovic, Maja +6 more
core +1 more source
Proprotein Convertase Subtilisin/Kexin Type 9 [PDF]
The American Journal of Pathology, 2021 Chiara Macchi +5 more
openaire +1 more source
British Journal of Pharmacology, EarlyView.Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang +18 more
wiley +1 more source
The E3 ubiquitin ligase c-IAP1 regulates PCSK9-mediated LDLR degradation: Linking the TNF-α pathway to cholesterol uptake [PDF]
, 2010 Proprotein convertase subtilisin/kexin type 9 (PCSK9), in addition to LDLR (low-density lipoprotein receptor) and APOB (apolipoprotein B), is one of three loci implicated in autosomal dominant hypercholesterolaemia (ADH)^1^.
Lizhi Liu, Weiming Xu
core +1 more source
FoxO3 transcription factor and Sirt6 deacetylase regulate LDL-cholesterol homeostasis via control of the proprotein convertase subtilisin/kexin type 9 (Pcsk9) gene expression [PDF]
, 2013 Elevated LDL-cholesterol is a risk factor for the development of cardiovascular disease. Thus, proper control of LDL-cholesterol homeostasis is critical for organismal health.
Deng, Chu-Xia +4 more
core +1 more source
Identification of Novel Proteins Interacting with Proprotein Convertase Subtilisin/Kexin 9
International Journal of Biomedical Investigation, 2020 High levels of cholesterol, especially as low-density lipoprotein (LDL), are a well-known risk factor for atherosclerotic-related diseases. The key atherogenic property of LDL is its ability to form atherosclerotic plaque. Proprotein convertase subtilisin/kexin-9 (PCSK9) is an indirect regulator of plasma LDL levels by controlling the number of LDL ...
Melendez, Quantil M. +5 more
openaire +2 more sources
Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels
Journal of Lipid Research, 2010 Over the past several years, proprotein convertase subtilisin kexin type 9 (PCSK9) has gained significant attention as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Jason S. Troutt +3 more
doaj +1 more source
Mìžnarodnij Endokrinologìčnij Žurnal, 2023 Diabetic dyslipoproteinemia (DLP), characterized by quantitative, qualitative, and kinetic changes in all major circulating lipids, contributes to an increased risk of atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (DM).
V.A. Serhiyenko, A.A. Serhiyenko
doaj +1 more source
Proprotein convertases in high-density lipoprotein metabolism [PDF]
, 2013 The proprotein convertase subtilisin/kexins (PCSKs) are a serine endopeptidase family. PCSK members cleave amino acid residues and modulate the activity of precursor proteins.
Ron Korstanje, Seungbum Choi
core +1 more source
Phenotypic homozygous familial hypercholesterolemia successfully treated with proprotein convertase subtilisin/kexin type 9 inhibitors [PDF]
, 2023 Ryosuke Tani +5 more
openalex +1 more source